← All news

HollandBIO welcomes Simmunext Biotherapeutics as a new member

HollandBIO connects, represents and supports the Dutch life science sector. We are very proud that we already represent over 270 companies: from start-ups, small and medium-sized companies to large companies, active in health, food or biobased economy. Today we welcome Simmunext Biotherapeutics! Simmunext likes to address a word to the reader:

Immunotherapy has seen great progression over the past decade, with some impressive results in cancer and autoimmune disease. Next to vaccines and antibody therapy, a commonly applied form of immunotherapy is based on isolating immune cells from a patient, stimulating and expanding these cells in vitro, followed by re-administration of large numbers of activated immune cells back into a patient (adoptive cell therapy, ACT).

While ACT has demonstrated clear clinical benefit, it is also associated with several difficulties: for each individual patient cells need to be isolated, expensive and time-consuming manipulation in vitro in clean rooms and under GMP conditions is required, and the quality and quantity of the product is highly dependent on the immune condition of the individual patient.

Simmunext Biotherapeutics has been working towards a solution for these issues and develops an ‘off-the-shelf’ product based on a filamentous-shaped PIC polymer backbone to which immune-modulating proteins are coupled. Using this technology platform, called ‘immunofilaments’, we generate bioconjugates that are able to stimulate immune cells in a manner similar to natural antigen presenting cells and better than main competitors in the market. During the past years we have obtained preclinical proof of concept, amongst others using in vivo mouse models.

The next step is to translate our technology into the clinic. Human applications might involve ex vivo treatment of T cells in ACT protocols, as well as direct administration of immunofilaments to cancer patients. The latter approach would obviate the need for the ex vivo protocol altogether.

For reference purposes a short list of publications is attached. In case of any questions, please contact Henri Theunissen, CEO Simmunext Biotherapeutics BV at henri@simmunext.com or M+31625140815.

← All news

HollandBIO welcomes TargED Biopharmaceuticals as a new member

HollandBIO connects, represents and supports the Dutch life science sector. We are very proud that we already represent over 270 companies: from start-ups, small and medium-sized companies to large companies, active in health, food or biobased economy. Today we welcome TargED Biopharmaceuticals, that was selected last week as one of the ten most promising academic start-ups – congratulations!

TargED Biopharmaceuticals B.V. is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis. TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. The lead compound is Microlyse, which is currently under development for thrombotic thrombocytopenic purpura (TTP) and Acute Ischemic Stroke (AIS). The objective is to accelerate thrombolysis in all forms of thrombosis, irrespective of the thrombus composition.

TargED, a spin-off of the University Medical Center Utrecht, was founded in July 2020 by Associate Professor at the Department of Clinical Chemistry and Haematology, Coen Maas, PhD, an expert in thrombosis and hemostasis, Steven de Maat, PhD, an expert in recombinant protein development and optimization, Marc van Moorsel, researcher with focus on Acute Ischemic Stroke and Kristof Vercruysse, with more than 20 years of experience in bringing biopharmaceutical compounds from pre-clinical proof of concept to market, most notably, Caplacizumab for Thrombotic Thrombocytopenic Purpura at Ablynx between 2007 and 2013.

← All news

Official biotech partnership Massachusetts & the Netherlands


It’s official! Massachusetts Life Sciences Center and Health~Holland signed the Program of Cooperation (PoC) between the life sciences ecosystems of Massachusetts and the Netherlands, co-signed by HollandBIO. The activities vary from financing to healthcare systems, from start- and scale-ups to academic researchers. It includes activities like the Henri Termeer Transatlantic Connection Award, with an exchange program and fellowship program, workshops and an investor conference. The goal of this PoC is to further strengthen the Transatlantic Life Sciences Partnership.
From MoU to PoC 

This Program of Cooperation (PoC) is an official follow-up of the earlier aspirations of the Memorandum of Understanding (MoU), which was signed in 2019. In the time being, signatories kept in touch with each other and kept thinking about the next steps for the partnership in two key stakeholder sessions in 2020 en 2021. Thanks to the ongoing contact and tide connections, especially made possibly by Mart Duitemeijer from the Netherlands Innovation Network in Boston, we were able to sign the PoC last Thursday.  


MOITI Massachusetts Office of International Trade and Investment, MassBio, Massachusetts Life Sciences Center, The Termeer Foundation, Ministerie van Economische Zaken en Klimaat, Vereniging Innovatieve Geneesmiddelen, Health~Holland and HollandBIO together emphasize the strategic importance of the life sciences sector and will provide their support in accelerating the growth of their life sciences hubs and the global opportunities for companies and research organizations.  

HollandBIO is proud to be a co-signatory. This partnership will boost the life sciences ecosystems of the Netherlands and Massachusetts to improve patients’ lives and contribution to a healthy society!   

← All news

HollandBIO verwelkomt Advanced Interim Management (AIM) als nieuw lid

HollandBIO is blij om Advanced Interim Management (AIM) te mogen verwelkomen! AIM is een Supply Chain consultancy bedrijf gevestigd aan de Westerkade in Rotterdam, dat zich specifiek en uitsluitend richt op de behoeften van de life science industrie. AIM is gespecialiseerd in het ondersteunen van new market entrants die hun eerste pharma, biotech, ATMP product of medical device op de markt willen brengen in Europa, maar ook in de US of andere delen van de wereld.

Inmiddels hebben wij sinds onze oprichting in 2009 meer dan 75 bedrijven succesvol bij dit proces ondersteund. Daarnaast ondersteunen wij onze meer gevestigde klanten met Supply Chain optimalisatie vraagstukken en door het leveren van interim Supply Chain specialisten op alle niveaus in de organisatie.  

Kenmerkend voor de werkwijze van AIM zijn het feit dat we niet alleen adviseren maar ook (helpen) uitvoeren en dat we uitsluitend werken met zeer ervaren consultants die de taal van onze klanten spreken. We voeren onze opdrachten uit op basis van heldere afspraken met onze klanten over resultaten, kosten en doorlooptijden. Sinds 2021 is AIM onderdeel van Blue Matter Consulting, een Amerikaans strategisch consultancy bedrijf, eveneens specifiek gericht op de life science industrie, met vestigingen in onder andere San Francisco, New York, Londen, Boston, India en Zürich.  

Speciale aandacht willen wij in deze introductie tot slot nog vestigen op onze webinar “Supply Chains for Cell & Gene Therapies: Orchestrating a Successful Launch & Beyond” die op 20 oktober 2022 om 17:00 CET zal plaatsvinden en via de link op onze website te bereiken zal zijn.

Kijk verder voor meer informatie op www.aimconnection.eu of neem contact met op via info@aimconnection.eu.

← All news

HollandBIO welcomes Bone-Tech as a new member

HollandBIO connects, represents and supports the Dutch life science sector. We are very proud that we already represent over 270 companies: from start-ups, small and medium-sized companies to large companies, active in health, food or biobased economy. Today we welcome Bone-Tech!

Bone-Tech is a joint venture between Osteo-Pharma and Emultech, developing what could be the first disease-modifying treatment for osteoarthritis of the knee. Bone-Tech brings together Osteo-Pharma’s novel combination drug therapy for the local treatment of osteoarthritis with Emultech’s world-leading microfluidics’ microspheres technology. Bone-Tech’s patented OsteoActivatorTM microspheres treatment promises to be the first and only extended-release treatment targeting subchondral bone remodelling for patients suffering from osteoarthritis-related pain and disability.

← All news

The next frontiers in cancer vaccines: when academia’s and industry’s bright minds get together

, , , ,

During the 3rd edition of the Biotech Wednesday Event, co-organized by HollandBIO and Oncode Institute, academia and industry came together to discuss the past, present and future of therapeutic cancer vaccines. In a packed Pakhuis de Zwijger, the brightest scientists and industry leaders in the cancer vaccine development shared their research and new developments including an outlook on the future.

HollandBIO’s Wieteke Wouters and Oncode’s Valorization Director Chris De Jonghe welcomed everybody and stressed the importance of collaboration. We have the power to reach over 270 biotech companies and more than 900 excellent cancer researchers. They established the goal of this event: to connect both the academic and industrial worlds.

The past, present and future of therapeutic cancer vaccines

Oncode Investigator Sjoerd van der Burg, (Leiden University Medical Center) kicked off with setting the scene about the past, present and future of cancer vaccines. Cancer vaccines know an exciting as well as frustratingly long history since the 1900’s, with lots of setbacks due to a lack of strong efficacy during trials. In order to improve therapeutic outcomes, more focus on CD4+ T-cells, T-cell infiltration and the selection of the appropriate neoantigens is needed.

Next up was Gerben Moolhuizen (CEO of ISA Pharmaceuticals). Gerben discussed the challenging pivoting decisions a biotech company has to make in (pre)clinical development and the development of ISA as a company itself. One of the big challenges for a biotech company is; how should you divide your limited resources in the complex landscape of oncology drug development? He zoomed in on the Target Product Profile, which answers questions like the type of patients to include in your trials, how your product will compete with current Standard of Care and the manufacturing scale for approval.

Katka Franke, (Associate Director at CureVac Netherlands) worked at pre-clinical biotech startup Frame Therapeutics, before it was acquired in 2022 by CureVac. Frame discovered unique and shared neoantigens of different tumors that are the result of frameshift mutations that can be used to develop therapeutic cancer vaccines. This unique approach attracted CureVac. Katka shared the insights of being part of an acquisition by another company and the latest data on neoantigens research. She concluded that the combination of WGS with short- and long-RNA sequencing provides a complete tumor neoantigen landscape.

After the break,  Oncode Investigator Carl Figdor (Radboud University Medical Center) discussed the limitations of cellular immunotherapies and posed the question whether we can design synthetic ‘off-the-shelf’ solutions for immunotherapy. Food for thought from Carl’s side: Is it possible to skip dendritic cells and immediately activate T-cells?

Erik Manting (CEO of Mendus AB) became CEO of DCPrime in 2018 which was merged with Immunicum AB in 2021 and is now renamed to Mendus AB. Quite a journey for Erik and his team. He addressed the key challenge in today’s cancer therapy landscape. Tumor recurrence is responsible for the vast majority of cancer-related deaths. To prevent or delay tumor recurrence will therefore have a large impact on the treatment of cancer. According to Erik, cancer vaccination has the potential to provide for durable responses combined with a benign safety profile.

Cross border collaboration

Helen Lavender (Translational Scientist at Cancer Research UK) was the last speaker to join the stage. Oncode Institute recently announced a strategic alliance with Cancer Research UK’s new innovation organisation, Cancer Research Horizons. The alliance aims to foster innovation and collaboration between world-leading cancer researchers. Helen shared key preclinical data on CDD CHADOX1/MVA vaccination results in tumor growth inhibition and increased survival by combination therapy. This is a great example of an academic/industry collaboration crossboarders: the Ludwig Maximillian University and Vaccitech worked together to develop MAGE/NY-ESO1.

The session ended with a lively and intense panel discussions. Where does the sweet spot of treatment for cancer vaccines lies? Is it prophylactic or recurrence targeting? Among diverse modality of vaccine platforms, would there be a winner of all? There was a lot of interaction with the audience and it was interesting to see how the brightest minds had their own thoughts on the ongoing research. Because of the panel discussion, our speakers received more questions than they could answer during the networking drink.

Above all, one thing stood out: we need to work collaboratively and exchange knowledge to bring the most innovative therapies to the market for the benefits of cancer patients. We hope this Biotech Wednesday Event was the start of many new collaborations and we can’t wait to meet you for the next edition.

©2022 Photo’s: Nils van Houts.

← All news

HollandBIO verwelkomt Smart BioMaterials Consortium

Kunstmatige hartkleppen die als vanzelf door het lichaam worden opgenomen, slagaders die zichzelf zonder invasieve chirurgie herstellen, kaakbot dat met een gel kan aangroeien en allerlei andere zelfhelende materialen: de wereld van de biomaterialen en regeneratieve geneeskunde is vol beloftes. Smart Biomaterials Consortium (SBMC), sinds kort lid van HollandBIO, gaat ervoor zorgen dat nieuwe ontwikkelingen zo snel mogelijk bij de patiënt terecht komen.

SBMC versnelt de ontwikkeling van innovatieve biomaterialen voor de regeneratieve geneeskunde door een brug te slaan tussen fundamenteel onderzoek en de dagelijkse zorgpraktijk. Dat doet SBMC met een breed aanbod van gedeelde translationele platforms die de belangrijkste knelpunten aanpakken in de commercialisering van biomaterialen voor de regeneratieve geneeskunde.

In de ontwikkelfaciliteit op de TU/e-campus werken ondernemers en wetenschappers samen aan het optimaliseren van de productie en assemblage van bio- en biocompatibele materialen (inclusief hydrogels), het functioneel testen, beoordelen en voorspellen van implantaatfuncties en het oplossen van opschalingsproblemen voor klinische productie in een omgeving die voldoet aan Good Manufacturing Practice (GMP) voor de farmaceutische industrie. In de gezamenlijke pilotfabriek, die eind 2023 wordt geopend, ligt de focus op de industriële productie van biomaterialen en afbreekbare implantaten.

SBMC wordt medegefinancierd door het Nationaal Groeifonds en de Provincie Noord-Brabant en is onderdeel van RegMed XB, een netwerk van vier initiatieven die samen de landelijke RG proeffabriek voor regeneratieve geneeskunde vormen. In Leiden werkt NecstGen aan nieuwe cel- en gentherapieën. Het UMC Utrecht is verantwoordelijk voor de ontwikkeling van microweefsels en in Maastricht levert ReGen Biomedical macroweefsels die nodig zijn voor de ontwikkeling van gepersonaliseerde regeneratieve therapieën.

Meer informatie: www.smartbiomaterials.nl

← All news

Praat mee deze vrijdag mee over Biotech Booster

Biotech ondernemers, Nederland heeft jullie nodig! Op 30 september om 15:00 uur organiseert HollandBIO een digitale bijeenkomst voor HollandBIO-leden om mee te praten over de uitwerking van het Biotech Booster groeifondsproject. Op 14 april heeft Biotech Booster €250 miljoen toegekend gekregen van het kabinet. Met het Groeifondsproject gaan we valorisatie van onze excellente biotech-brede kennisbasis verbeteren. De ervaring van ondernemers is daarbij onmisbaar. En daarom horen we aanstaande vrijdag ook graag wat jullie vinden! HollandBIO-leden registeren zich hier

Eén belangrijk uitgangspunt van Biotech Booster is het benutten van de ervaring en expertise van biotech ondernemers. Jullie weten immers als geen ander hoe je beloftevolle vindingen vanuit kennisinstellingen op een bedrijfsmatige en efficiënte manier ontwikkelt tot investeerbare assets en welke mogelijkheden en uitdagingen daarbij komen kijken. 

Input van de ondernemers in onze achterban is onmisbaar voor het slagen van Biotech Booster. We nodigen je dan ook van harte uit om met ons mee te denken over het voorstel: welke praktische haken en ogen zie je, welke mogelijkheden zijn er en welke rol is er weggelegd voor ondernemers en bedrijven? Ook lichten we het voorstel en de stappen tot nu toe en in de komende tijd nader toe. 


Om zoveel mogelijk input te verzamelen, organiseren wij twee digitale bijeenkomsten om mee te praten. Afgelopen vrijdag was de eerste sessie, komende vrijdag, 30 september, om 15:00 uur volgt de tweede. Deze is uitsluitend bestemd voor HollandBIO-leden. Daarom vragen we je via onderstaande link te registreren. 

Aanmelden voor 30 september: https://hollandbio.odoo.com/event/praat-mee-biotech-booster-kopie-2022-09-30-264/register

← All news

Kabinet wil samenwerken om grote veranderingen landbouw, klimaat en zorg op te lossen – Prinsjesdag 2022

, , , , ,

We leven, zoals Koning Willem-Alexander in de Troonrede aanhaalde, in een tijd van tegenstrijdigheden en onzekerheid. Economische groei en lage werkloosheid staan tegenover uitdagingen rond de energiecrisis, stikstof, klimaat en de toekomst van de zorg. Het kabinet wil graag dat Nederland zelf koers bepaalt en stap voor stap en in nauwe samenwerking het hoofd biedt aan de grote veranderingen die op ons afkomen. HollandBIO is ervan overtuigd dat innovaties en ideeën uit de biotechnologie van doorslaggevend belang zijn: voor verduurzaming, zorg en ons verdienvermogen. Daarom maken wij graag, samen met de overheid, werk van de oplossingen van vandaag en morgen.

In de Troonrede, ditmaal uitgesproken in de Koninklijke Schouwburg in Den Haag, ging de Koning in op de vele grote veranderingen die ons tegemoet komen en hoe we daar in Nederland het beste mee om kunnen gaan. Vanuit het perspectief van de biotech sector viel vooral de aandacht voor klimaat, energie, landbouw, stikstof, zorg en het (toekomstige) Nederlandse verdienvermogen op. Daarbij ging de Koning ook in op de rol die nieuwe oplossingen, technologie en innovatieve start-ups spelen in het aangaan van deze uitdagingen.

Grote veranderingen en ingrijpende ontwikkelingen verlopen vaak stapsgewijs en in nauwe samenwerking. Zo benadrukte de Koning dat “[de wereld] anders zal zijn, want onze huidige manier van leven stuit op economische, sociale en ecologische grenzen. Dat vergt een andere economie en arbeidsmarkt. Een andere omgang met ruimte en natuur. Andere manieren van wonen, werken, ondernemen en reizen. En andere vormen van samenleven.” Het is precies die boodschap die ook zijn weerklank vindt in de Biorevolutie, een vooruitblik op hoe biotechnologie en andere technologieën de samenleving gaan veranderen in de komende jaren. Ook daar blijkt immers dat niet minder dan 70% van de maatschappelijke impact zit in de mate waarin we als samenleving erin slagen om innovaties en oplossingen te omarmen.

Miljoenennota 2023: miljarden voor crisesbestrijding

In de Miljoenennota voor het jaar 2023 staan onzekerheden centraal, iets waar de Koning ook al ruimschoots op inging tijdens de Troonrede: de oorlog in Oekraïne en oplopende inflatie als gevolg van onder andere stijgende energie- en grondstofprijzen nopen het Kabinet tot actie. Daar trekt zij ook de knip voor, met een koopkrachtplan van bijna 18 miljard euro dat zich richt op mensen en huishoudens met lage- en middeninkomens. Omdat het Kabinet de staatsschuld stabiel en houdbaar wil laten blijven, houdt dit aan de andere kant in dat zij bezuinigingen en besparingen gaat doorvoeren: zo gaan het lage tarief van de vennootschapsbelasting en de belastingen op vermogen omhoog.

Op klimaat maakt de overheid verder werk van het Klimaatfonds van 35 miljard euro, waarbij zij daarnaast nog ambitieuzere doelstellingen gaat hanteren met een doel van 60% emissiereductie in 2030 en 100% in 2050. Om dit te bereiken, wil de overheid ook verdergaande normering en beprijzing gaan toepassen rond bijvoorbeeld CO2 en stimulering via duurzaamheidssubsidies als de SDE++.

Op het gebied van curatieve zorg staat het recent gelanceerde Integraal Zorgakkoord in de schijnwerpers, waarin het verder beperken van de uitgaven aan innovatieve geneesmiddelen, het beter gebruiken van data en uitwisselen van gegevens in de zorg en de manier waarop we met preventie omgaan aan bod komt. Daarnaast reserveert de overheid 200 miljoen euro voor de versterking van de publieke gezondheidszorg en pandemische paraatheid, om daarmee goed zicht te houden op (potentiële) pandemieën. Het kabinet maakt tevens bekend dat er 15,4 miljoen euro beschikbaar komt om vanaf 2024 de vaccinatie voor baby’s tegen het Rotavirus onderdeel te maken van het Rijksvaccinatieprogramma. Op zich goed nieuws natuurlijk, al blijft HollandBIO hameren op het preventief budgetteren voor bewezen effectieve vaccinatie.

Al met al is dit de eerste afdronk van Prinsjesdag. Nu alle documenten gepubliceerd zijn, duikt HollandBIO verder de begroting van de verschillende ministeries in. In aanloop naar de inhoudelijke behandeling blikken we verder vooruit op wat het komende jaar ons brengen zal.

← All news

The power of biotech proves to be not only effective for the future – Throwback Dutch Biotech Event 2022

, , , , ,

I couldn’t have welcomed you any better, cheered HollandBIO’s Annemiek after the video message of Minister Robbert Dijkgraaf, Ministry of Education, Culture and Science at HollandBIO’s Dutch Biotech Event 2022. Robbert Dijkgraaf spoke full of promise about our Dutch biotech sector: ‘Worldwide biotech saved us these last few years.’

The Princeton professor and now Science Minister spoke about the past (‘the covid vaccines were more successful, effective and faster developed than we could have dreamt’), but also about the future (‘The power of biotech is also promising for the future. After all, the Netherlands has a unique position in terms of our strength in life sciences research and the collab between brightest minds, beautiful corporations and world class institutions’). And last but not least, he acknowledged the promise of Biotech Booster that was assigned €250 million out of the National Growth Fund to improve biotech valorization.

Speaking of the brightest minds, the winner of the Venture Challenge Spring 2022 was announced on stage. The Venture Challenge is a 10-week program to develop an initial idea in life sciences into a solid business case. Startup Iprotics, that develops specific proteasome inhibitors that potentially treat multiple myeloma without the side-effects known from traditional proteasome inhibitors, won this edition.

Jeroen Hugenholtz, expert in food fermentation and co-founder of startup company NoPalm Ingredients had this year’s honor to present his keynote to the Dutch biotech ecosystem. NoPalm Ingredients is an alternative fat company that first of all is producing a sustainable alternative for palm oil. Jeroen concluded that fermentation makes live better. HollandBIO agrees on the bigger picture that biotech makes live better.

After the plenary sessions, the attendees had the chance to visit several break-out sessions that have connections with biotech and entrepreneurship:   

National Growth Fund: Opportunities for biotech entrepreneurs

Four growth fund projects presented themselves and what they have to offer biotech entrepreneurs with the hundreds of millions in subsidies they will be receiving. Koen Daamen, Sector Lead Health & Care at National Growth Fund, was our moderator for this session. Cellular Agriculture, PharmaNL, Crop-XR and Biotech Booster took the stage for a short 5 minute pitch and questions. This carousel of growth fund proposals was a good conversation starter for the networking drinks.

Talent in turbulent times

Building a biotech company rarely is a linear uphill road. Promising results trigger exponential growth, whereas setbacks unavoidably lead to lay-offs. Adding the surging demand for, and scarcity of talent to the mix, and you’ll understand why your people strategy can make or break your company. How to navigate this inherent uncertainty from a human capital perspective? And how to attract and retain talent for a lifelong career in life sciences under these challenging circumstances? Lilian Hendrick (VP Human Capital at Agendia), Vera van Proosdij (Head of People at Mosa Meat) and Wiebe Teeuwen (Partner & BD director at QTC Recruitment) shared their insights on how a company’s purpose, communication and culture are key for people. Besides, in a lively discussion opportunities to join forces were explored, for instance via talent pools.

Early Stage Term Sheet Negotiation Game

Crawl across the table and put yourself in someone else’s skin – to increase the understanding of what it means to negotiate a term sheet in the early stage, Ruud Smits and Sybren de Beurs of NautaDutilh first showed us which fears and wishes both sides of the negotiation table have. They explained the possible elements of a early stage term sheet, before they put the group to work at the negotiation table themselves – encouraged by several skilled NautaDutilh’ colleagues. There, both the investors and founders experienced firsthand how hard it can be to get a handshake deal. Fortunately, at the end of the day, the negotiators were able to toast to a successful outcome – a bit wiser and more experienced than before.

How to survive & thrive in today’s bear biotech market

During this session Jan de Kerpel (Co-Head Corporate Finance at Kempen & Co) gave an insightful introduction on key trends in the life science sector regarding fundraising, mergers and acquisitions. Over the last 10 years companies are getting bigger, a parameter that our ecosystem is getting bigger. Jacquelien ten Dam (CFO at Mimetas) and Paul van der Horst (CBO at AgomAb Therapeutics) joined Jan de Kerpel on stage for a more detailed discussion on the current financial situation and conclude how “perseverance” is a beautiful take home message.

(Lab)space to grow your biotech startup

To grow as a biotech startup, you need adequate lab space to develop your products. With interesting talks by Janneke Meulenberg (MeiraGTx), Mauro Muraro (Single Cell Discoveries), Johan van Gerven (Kadans Science Partner) and Richard Rushby (Innolabs) led by Gonja van Hardeveld (Thermo Fisher Scientific) we discussed how biotech companies can find or realize adequate lab space. We found that cooperation and dialogue between all involved partners is key. By identifying upcoming demand for lab space before it’s urgently needed, developers can work to provide the best lab space possible.  

More than 200 participants joined us on Friday 9th of September and over networking drinks and a BBQ they had time to invest in meeting new potential partners for the future.

We want to thank all our attendees and speakers for creating again a beautiful event. We see you around at one of our other events!

©2022 Photo’s: Nils van Houts